Juan Cuevas, MD
Medical Oncology · Bridgeton, MONPI 1295727493
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,062 of the $5,407 with a category attached, or 75.1%. 43 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.3% of the total. Reporting peaked in 2019 at $2,939 and has fallen 93.6% since, to $189 in 2025.
Across 188 payments — averaging $28.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Novartis$295
- Genentech USA, Inc.$249
- Gilead$235
- ASD Specialty Healthcare, LLC$225
- Lilly USA, LLC$220
- plus $3K from 37 others
Across 105 payments — averaging $2498.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$50K
- Beone Medicines Ltd.$45K
- AstraZeneca$43K
- EMD Serono, Inc.$32K
- Janssen Research & Development, LLC$29K
- G1 Therapeutics, Inc.$20K
- plus $45K from 9 others
What the payments were for
- Consulting fees$1,20022%
- Food & beverage$4,06275%
- Education$1453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,407 in reported general payments places this provider in the 55th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 52 | $976,903 |
| CalquenceAcalabrutinib Maleate | 49 | $666,328 |
| XtandiEnzalutamide | 37 | $488,892 |
| ImbruvicaIbrutinib | 17 | $276,698 |
| LorbrenaLorlatinib | 12 | $257,604 |
| PromactaEltrombopag Olamine | 12 | $236,810 |
| InlytaAxitinib | 12 | $219,417 |
| JakafiRuxolitinib Phosphate | 12 | $210,876 |
| IbrancePalbociclib | 12 | $184,168 |
| BrukinsaZanubrutinib | 12 | $181,102 |
| KisqaliRibociclib Succinate | 13 | $179,950 |
| Abiraterone Acetate | 74 | $153,585 |
| EliquisApixaban | 21 | $17,459 |
| Everolimus | 12 | $14,322 |
| Anastrozole | 258 | $4,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $146 | $976,90352 claims |
| PfizerLorbrena, Inlyta, Ibrance, Eliquis | $198 | $678,64857 claims |
| AstraZenecaCalquence | $116 | $666,32849 claims |
| Astellas Pharma US IncXtandi | $13 | $488,89237 claims |
| NovartisPromacta, Kisqali | $295 | $416,76025 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $67 | $276,69817 claims |
| Incyte CorporationJakafi | $49 | $210,87612 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $23 | $34629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Bridgeton
- Leonid ShunyakovBolivar$2.1M
- Timothy PluardKansas City$664K
- Brad KahlSaint Louis$336K
- Michael NaughtonCape Girardeau$249K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.